Literature DB >> 31923540

Subchronic toxicological evaluation of Bojungikki-tang water extract: 13-Week oral repeated-dose toxicity study in Crl:CD (SD) rats.

Woo-Young Jeon1, Chang-Seob Seo2, Hyekyung Ha3, Hyeun-Kyoo Shin4, Jae-Woo Cho5, Da Hee Kim6, Mee-Young Lee7.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Bojungikki-tang is a traditional herbal medicine used to boost immunity and reduce fatigue. However, there is not enough scientific evidence about its toxicological safety profile to support its continued clinical application. AIM OF THE STUDY: The objective of this study was to investigate the subchronic toxicity profile of Bojungikki-tang water extract (BITW) in Sprague Dawley rats who were exposed to it in multiple doses and various concentrations.
MATERIALS AND METHODS: BITW was administered to rats orally, once daily at doses of 0, 500, 1000, or 2000 mg/kg/day for 13 weeks. We checked toxicological parameters including general observations, organ/body weights, food consumption, ophthalmological signs, hematological and serum biochemical values, urinalysis values and histopathological findings.
RESULTS: The 13 week repeated oral administration of BITW to rats at doses at doses levels of less than or equal to 2000 mg/kg/day caused no significant toxicological changes and only minor nonsignificant changes.
CONCLUSIONS: Our findings indicate that administration of BITW for up to 13 weeks may be safe and nontoxic, with a no-observed-adverse-effect-level of >2000 mg/kg/day for both male and female rats.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bojungikki-tang; NOAEL; Safety evaluation; Subchronic toxicity; Traditional herbal medicines

Year:  2020        PMID: 31923540     DOI: 10.1016/j.jep.2020.112551

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  2 in total

1.  Efficacy and Safety of Bojungikgi-Tang for Persistent Allergic Rhinitis: A Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Authors:  Su Won Lee; Jin Kwan Choi; Yee Ran Lyu; Won Kyung Yang; Seung Hyung Kim; Je Hyun Kim; Si Yeon Kim; Weechang Kang; In Chul Jung; Beom Joon Lee; Jun Yong Choi; Taesoo Kim; Yang Chun Park
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-20       Impact factor: 2.650

2.  Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing Mice.

Authors:  Jaemoo Chun; Sang-Min Park; Jin-Mu Yi; In Jin Ha; Han Na Kang; Mi-Kyung Jeong
Journal:  Front Pharmacol       Date:  2022-07-06       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.